Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max Julve

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Expert Opinion on Biological Therapy|March 18, 2023
Advances in the development of tumor-infiltrating lymphocyte therapy for advanced melanomaMax Julve, Andrew Js Furness
Cancer Communications (London, England)|October 15, 2025
Tumor-infiltrating lymphocyte therapy and the mucosal melanoma treatment landscapeJennifer Thomas, Max Julve, James Larkin, et al.
Trends in Cancer|May 9, 2024
Lifileucel: the first cellular therapy approved for solid tumoursMax Julve, Mark P Lythgoe, James Larkin, et al.
Journal of Clinical Pathology|October 19, 2023
Gene of the month: cancer testis antigen gene 1b (NY-ESO-1)Max Julve, Oliver Kennedy, Adam Enver Frampton, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Expert Opinion on Biological Therapy|March 18, 2023
Advances in the development of tumor-infiltrating lymphocyte therapy for advanced melanomaMax Julve, Andrew Js Furness
Cancer Communications (London, England)|October 15, 2025
Tumor-infiltrating lymphocyte therapy and the mucosal melanoma treatment landscapeJennifer Thomas, Max Julve, James Larkin, et al.
Trends in Cancer|May 9, 2024
Lifileucel: the first cellular therapy approved for solid tumoursMax Julve, Mark P Lythgoe, James Larkin, et al.
Journal of Clinical Pathology|October 19, 2023
Gene of the month: cancer testis antigen gene 1b (NY-ESO-1)Max Julve, Oliver Kennedy, Adam Enver Frampton, et al.
Pageof 1